In Vivo Compound Efficacy Evaluation

The Benefits
Taconic's in vivo compound profiling program may accelerate the drug discovery process by:

• quickly assessing the therapeutic efficacy of lead compounds and/or drug development candidates by analyzing their key physiological effects in rodents;
• screening for potential side effects caused by the administration of such compounds at relevant doses;
• identifying and/or confirming new disease indications for such experimental compounds that were not previously known, thus expanding the market potential of those drug candidates.

The team
Taconic's multidisciplinary team of Ph.D. level scientists, including physiologists, immunologists, pharmacologists, behavioral scientists, biochemists and molecular biologists, all working closely with you to quickly bring your project to the next phase of the drug discovery process.

Custom-Designed Programs
Taconic understands that the research needs for an efficacy evaluation of therapeutics may vary widely, depending on the stage and specific goals of the drug discovery and development program. With nearly 100 standardized and validated bioassays measuring approximately 450 parameters, Taconic's in vivo compound profiling program is designed to provide readouts in preclinical models of disease, as well as to interrogate the key physiological pathways associated with various diseases and therapeutic areas.

Taconic scientists have extensive experience performing efficacy studies with small molecule compounds, large molecule biologics/antibodies, stem cell therapeutics, RNAi therapeutics and nanoparticles by commonly used routes of administration. We will work closely with you to custom design each program to best meet your research goals, with the aim of providing interpretive data analysis tailored to your specifications. Our collective expertise in multiple therapeutic areas allows Taconic to effectively assess disease manifestations related to a wide range of physiological systems in rodents.

Taconic's in vivo compound profiling program is designed to profile the following key therapeutic area and disease platforms:

• Arthritis Platform
• Autoimmune Diseases
• Cardiovascular Diseases
• Diabetes
• Gastrointestinal Disorders
• Inflammation and Allergy
• Neurodegenerative Disorders
• Neuropathic and Disease Associated Pain
• Obesity
• Oncology
• Psychiatric Disorders
• Sexual Health
• Tissue Repair
• Urological Disorders

In addition, Taconic's non-invasive biophotonic imaging platform supports the determination and evaluation of biodistribution kinetics of various experimental agents through the use of fluorescently-labeled antibody molecules, fusion proteins, co-administered carrier molecules, and more. A collection of light-producing gram-positive and gram-negative bacteria enables Taconic to perform non-invasive biophotonic imaging studies for the purpose of evaluating select classes of anti-infective agents (such as certain antibiotics) or for evaluating the composition of certain experimental prosthetic devices for their ability to resist certain forms of bacterial biofilm growth.

• Bacterial Biofilm Paradigms
• Biodistribution of bioluminescently and/or fluorescently-labeled test agents (or DNA or RNA test agents expressing bioluminescent molecules) in healthy animals or in disease models

The Bottom Line
Taconic's in vivo compound profiling program can achieve significant savings in time and money because it provides clinically-relevant efficacy and side effects data earlier in the drug discovery process.

In short, Taconic's in vivo compound profiling program, in combination with Taconic's state-of-the-art custom model generation services, breeding services and colony management services, can accelerate your research process and consequently, accelerate the introduction of tomorrow's life enhancing drugs to the marketplace.